YS BIOPHARMA CO LTD (YS) Stock Price, Forecast & Analysis
USA - NASDAQ:YS - KYG9845F1090 - Common Stock
YS Key Statistics, Chart & Performance
The current stock price of YS is 1.02 USD. In the past month the price increased by 27.5%. In the past year, price decreased by -22.73%.
YS Latest News, Press Relases and Analysis
YS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About YS
Company Profile
YS Biopharma Co. Ltd. operates as a biopharmaceutical company, which is dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing and currently employs 773 full-time employees. The company went IPO on 2021-07-30. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
Company Info
YS BIOPHARMA CO LTD
Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park
Beijing BEIJING CN
Employees: 773
Phone: 17327133678
YS BIOPHARMA CO LTD / YS FAQ
What does YS do?
YS Biopharma Co. Ltd. operates as a biopharmaceutical company, which is dedicated to discovering, developing, manufacturing and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company is headquartered in Beijing, Beijing and currently employs 773 full-time employees. The company went IPO on 2021-07-30. The firm's vaccine product YSJATM rabies vaccine has been commercialized. The firm also has four product candidates under various clinical development stages, including PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, PIKA YS-ON-001 and PIKA YS-HBV-001, and four preclinical stage product candidates, targeting HBV, influenza and cancer with enormous medical demand. In addition, the Company is working on a series of therapeutic targets, rabies and products at the discovery stage.
What is the stock price of YS BIOPHARMA CO LTD today?
The current stock price of YS is 1.02 USD. The price increased by 12.45% in the last trading session.
What is the dividend status of YS BIOPHARMA CO LTD?
YS does not pay a dividend.
What is the ChartMill rating of YS BIOPHARMA CO LTD stock?
YS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in YS BIOPHARMA CO LTD be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on YS.
What is YS BIOPHARMA CO LTD worth?
YS BIOPHARMA CO LTD (YS) has a market capitalization of 192.10M USD. This makes YS a Micro Cap stock.
Who owns YS BIOPHARMA CO LTD?
You can find the ownership structure of YS BIOPHARMA CO LTD (YS) on the Ownership tab.
YS Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to YS. When comparing the yearly performance of all stocks, YS is one of the better performing stocks in the market, outperforming 96.68% of all stocks.
YS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to YS. Both the profitability and financial health of YS have multiple concerns.
YS Financial Highlights
Over the last trailing twelve months YS reported a non-GAAP Earnings per Share(EPS) of -0.42. The EPS decreased by -9348.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.59% | ||
| ROE | -50.88% | ||
| Debt/Equity | 0.65 |
YS Forecast & Estimates
9 analysts have analysed YS and the average price target is 4.26 USD. This implies a price increase of 317.5% is expected in the next year compared to the current price of 1.02.
For the next year, analysts expect an EPS growth of 19.72% and a revenue growth -6.61% for YS